In the largest study of its kind to date, researchers across 11 centers analyzed data on a relatively new minimally invasive alternative surgery for epilepsy, and discovered changes that could make the procedure more effective in both laser ablation and standard surgery.
This study evaluated the feasibility and generalizability of using regular expressions to identify SUDEP risk factors in electronic medical records and barriers to generalizability.
The FDA has approved the first nasal spray rescue medication to treat seizure clusters in people over 12 years of age and older with epilepsy.
Objective: To describe the mode of onset of SCN8A-related severe epilepsy in order to facilitate early recognition, and eventually early treatment with sodium channel blockers. Methods: Researchers reviewed the phenotype of patients carrying a mutation in the SCN8A gene, among a multicentric cohort of 638 patients prospectively followed by several pediatric neurologists. The study focused on the way clinicians made the diagnosis of epileptic encephalopathy, the very first symptoms, electroencephalography (EEG) findings, and seizure types. The team made genotypic/phenotypic correlation based on epilepsy-associated missense variant localization over the protein. Results: The study found 19 patients carrying a de novo mutation of SCN8A, representing 3% of our cohort, with 9 mutations being novel. Age at onset of epilepsy was 1 day to 16 months. The team also found two modes of onset: 12 patients had slowly emerging onset with rare and/or subtle seizures and normal interictal EEG (group 1). The first event was either acute generalized tonic-clonic seizure (GTCS; Group 1a, n = 6) or episodes of myoclonic jerks that were often mistaken for sleep-related movements or other movement disorders (Group 1b, n = 6). Seven patients had a sudden onset of frequent tonic seizures or epileptic spasms with abnormal interictal EEG leading to rapid diagnosis of epileptic encephalopathy. Sodium channel blockers were effective or nonaggravating in most cases. Significance: SCN8A is the third most prevalent early onset epileptic encephalopathy gene and is associated with two modes of onset of epilepsy.
Brivaracetam is not associated with an increased level of anger in patients with either focal or generalized epilepsy, however an improvement in anger levels is possibly influenced by a good seizure response.